Tonix Pharmaceuticals Advances Fibromyalgia Drug Approval, Reports Q1 Financial Results

Tonix Pharmaceuticals Advances Fibromyalgia Drug Approval, Reports Q1 Financial Results

Tonix Pharmaceuticals Holding Corp. is advancing its strategic goals with a potential breakthrough in fibromyalgia treatment and promising developments across its research portfolio. The company is anticipating an FDA decision for TNX-102 SL, a non-opioid analgesic, with a target approval date of August 15, which could represent the first new drug class for fibromyalgia in over 15 years. The pharmaceutical company reported first-quarter financia…

Around the World Day of Fibromyalgia, the Fibromyalgie self-help group Bolzano also set an important signal to draw attention to the painful illness. Antonietta Trova, head of the Fibromyalgie self-help group Bolzano, invited the many people concerned and relatives to the Rosenbach-Saal in Bolzano in order to foster exchange and strengthen solidarity among those affected. Exchange and experience Many people affected and relatives had responded t…

Release – Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights

Research News and Market Data on TNXP May 12, 2025 4:30pm EDT FDA PDUFA goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia; if approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years Announced positive topline results from Phase 1 study of TNX-1500, a next generation anti-CD40L mAb candidate in development for prevention of kidney transplant rejection and treatment of auto…

The association has reported on this disease at the door of the Reina Sofia Hospital The celebration of the International Day of Nurses in Cordoba, in images